Ligand Pharmaceuticals: Filspari和XOMA增强了买入理由 (纳斯达克:LGND)
· seekingalpha.com
Ligand Pharmaceuticals获得买入评级，得益于版税增长、XOMA交易以及Filspari势头推动盈利和前景。在此了解更多关于LGND的信息。
I am an Investment Research Analyst with a strong interest in fundamental equity research, valuation, and long-term investing, with a primary focus on the U.S. ...